Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children

Overview

Journal Children (Basel)

Specialty Health Services

Date 2022 Jul 27

PMID 35884064

Authors

Rebecca Dobra

Sian Bentley

Claire Edmondson

Maxine Ovens

Clare Saunders

Christopher Short

Gemma Wilson

Jane C Davies

Andrew Bush

Affiliations

Soon will be listed here.

Abstract

This is an exciting time for research and novel drug development in cystic fibrosis. However, rarely has the adage, "Children are not just little adults" been more relevant. This article is divided into two main sections. In the first, we explore why it is important to involve children in research. We discuss the potential benefits of understanding a disease and its treatment in children, and we highlight that children have the same legal and ethical right to evidence-based therapy as adults. Additionally, we discuss why extrapolation from adults may be inappropriate, for example, medication pharmacokinetics may be different in children, and there may be unpredictable adverse effects. In the second part, we discuss how to involve children and their families in research. We outline the importance and the complexities of selecting appropriate outcome measures, and we discuss the role co-design may have in improving the involvement of children. We highlight the importance of appropriate staffing and resourcing, and we outline some of the common challenges and possible solutions, including practical tips on obtaining consent/assent in children and adolescents. We conclude that it is unethical to simply rely on extrapolation from adult studies because research in young children is challenging and that research should be seen as a normal part of the paediatric therapeutic journey.

Citing Articles

Advances in the pathogenesis and personalised treatment of paediatric asthma.

Scotney E, Fleming L, Saglani S, Sonnappa S, Bush A BMJ Med. 2023; 2(1):e000367.

PMID: 37841968 PMC: 10568124. DOI: 10.1136/bmjmed-2022-000367.

Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis.

Conti J, Sorio C, Melotti P Children (Basel). 2023; 10(1).

PMID: 36670555 PMC: 9856584. DOI: 10.3390/children10010004.

References

Rowbotham N, Smith S, Leighton P, Rayner O, Gathercole K, Elliott Z . The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax. 2017; 73(4):388-390. PMC: 5870449. DOI: 10.1136/thoraxjnl-2017-210473. View

Schluter D, Ostrenga J, Carr S, Fink A, Faro A, Szczesniak R . Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data. Thorax. 2021; 77(2):136-142. PMC: 8581063. DOI: 10.1136/thoraxjnl-2021-216849. View

. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med. 1993; 329(18):1308-13. DOI: 10.1056/NEJM199310283291804. View

Aurora P, Stocks J, Oliver C, Saunders C, Castle R, Chaziparasidis G . Quality control for spirometry in preschool children with and without lung disease. Am J Respir Crit Care Med. 2004; 169(10):1152-9. DOI: 10.1164/rccm.200310-1453OC. View

Lange P, Celli B, Agusti A, Jensen G, Divo M, Faner R . Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015; 373(2):111-22. DOI: 10.1056/NEJMoa1411532. View

Gibson L, COOKE R . A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959; 23(3):545-9. View

Davies J, Sheridan H, Bell N, Cunningham S, Davis S, Elborn J . Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med. 2014; 1(8):630-638. DOI: 10.1016/S2213-2600(13)70182-6. View

Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F . Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis. Front Pediatr. 2021; 9:744705. PMC: 8634876. DOI: 10.3389/fped.2021.744705. View

. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule. Fed Regist. 1999; 63(231):66631-72. View

10.

McCormick J, Green M, Mehta G, Culross F, Mehta A . Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet. 2002; 10(10):583-90. DOI: 10.1038/sj.ejhg.5200850. View

11.

Stalvey M, Pace J, Niknian M, Higgins M, Tarn V, Davis J . Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor. Pediatrics. 2017; 139(2). PMC: 5260152. DOI: 10.1542/peds.2016-2522. View

12.

Domecq J, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N . Patient engagement in research: a systematic review. BMC Health Serv Res. 2014; 14:89. PMC: 3938901. DOI: 10.1186/1472-6963-14-89. View

13.

Olivier A, Yi Y, Sun X, Sui H, Liang B, Hu S . Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest. 2012; 122(10):3755-68. PMC: 3534166. DOI: 10.1172/JCI60610. View

14.

Dobra R, Elborn J, Madge S, Allen L, Boeri M, Kee F . Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study. J Cyst Fibros. 2021; 20(6):986-993. DOI: 10.1016/j.jcf.2021.03.021. View

15.

Balfour-Lynn I, King J . CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev. 2020; 42:3-8. PMC: 7255286. DOI: 10.1016/j.prrv.2020.05.002. View

16.

Harris J, Haltbakk J, Dunning T, Austrheim G, Kirkevold M, Johnson M . How patient and community involvement in diabetes research influences health outcomes: A realist review. Health Expect. 2019; 22(5):907-920. PMC: 6803418. DOI: 10.1111/hex.12935. View

17.

Nguyen T, Thia L, Hoo A, Bush A, Aurora P, Wade A . Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants. Thorax. 2013; 69(10):910-7. PMC: 4174068. DOI: 10.1136/thoraxjnl-2013-204023. View

18.

di SantAgnese P, DARLING R, PERERA G, Shea E . Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics. 1953; 12(5):549-63. View

19.

Rosenfeld M, Wainwright C, Higgins M, Wang L, McKee C, Campbell D . Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018; 6(7):545-553. PMC: 6626762. DOI: 10.1016/S2213-2600(18)30202-9. View

20.

Bobadilla J, Macek Jr M, Fine J, Farrell P . Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002; 19(6):575-606. DOI: 10.1002/humu.10041. View